Physician profile
Peter Rudzinskiy
NPI 1508081548
$1,799.01
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $12.12 · 2021: $538 · 2022: $594 · 2023: $72.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $72.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $72.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $297.44 | 2019 | |
| Abbvie INC. | $164.82 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $149.57 | 2019-2021 | |
| Biogen, INC. | $115.09 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $92.49 | 2021-2022 | |
| Amgen INC. | $85.38 | 2019-2022 | |
| Eisai INC. | $81.93 | 2019-2023 | |
| Neurelis, INC. | $79.41 | 2021-2022 | |
| Kyowa Kirin, INC. | $69.44 | 2022 | |
| Adamas Pharmaceuticals, INC. | $68.67 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $56.64 | 2022-2023 | Ultomiris |
| Neurocrine Biosciences, INC. | $55.61 | 2021-2022 | |
| Sk Life Science, INC. | $53.56 | 2021-2022 | |
| W. L. Gore & Associates, INC. | $50.69 | 2021 | |
| Acadia Pharmaceuticals INC | $44.13 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $41.65 | 2021 | |
| Argenx US, INC. | $41.15 | 2022 | |
| Ge Healthcare | $31.16 | 2019 | |
| Xeris Pharmaceuticals, INC. | $29.98 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $28.48 | 2022-2023 | Rytary |
| Acorda Therapeutics, INC | $28.26 | 2022-2023 | Inbrija |
| Lundbeck LLC | $27.96 | 2022 | |
| Mdd US Operations, LLC | $27.86 | 2022 | |
| Genzyme Corporation | $21.30 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.36 | 2022 | |
| Upsher-Smith Laboratories LLC | $14.64 | 2022 | |
| Alnylam Pharmaceuticals INC. | $13.35 | 2023 | Onpattro |
| Harmony Biosciences LLC | $12.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Rudzinskiy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.